The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
- 453 Downloads
Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair–deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.
KeywordsProgrammed death ligand-1 Immunotherapy Gynecologic cancer Ovarian cancer Endometrial cancer Cervical cancer
Compliance with Ethical Standards
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as •• Of major importance
- 1.FDA News Release. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. 2017. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm. Accessed Sept 27th 2017.
- 4.Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbial Immunol. 2011;350:17–37.Google Scholar
- 19.•• Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Management Working Group. J ImmunoTher Cancer. 2017;5:95 Guidelines for managing toxicities associated with checkpoint inhibition. CrossRefGoogle Scholar
- 22.Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65.CrossRefGoogle Scholar
- 27.Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trials: safety and clinical activity. J Clin Oncol. 2016; 34. Available at: http://meetinglibrary.asco.org/record/126089/abstract. Accessed Sept 27th 2017.
- 28.Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with PD-L1–positive advanced ovarian cancer: updated analysis of KEYNOTE-028 [ASCO abstract 5513]. J Clin Oncol. 2017;35(15 suppl).Google Scholar
- 29.Rauh-Hain JA, Brewster WR, Behbakht K. Society of Gynecologic Oncology 2018 Annual Meeting on Women’s Cancer: meeting report. Gynecol Oncol 2018; https://doi.org/10.1016/j.ygyno.2018.04.569. Accessed May 22 2018.
- 32.Hollebecque A, Meyer T, Moore KN, et al. An open-label multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol. 2017;34(suppl; abstr 5504).Google Scholar
- 33.Chung HC, Schellens JHM, Delord J-P, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2018;36(suppl; abstr 5522).Google Scholar
- 34.Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefGoogle Scholar
- 39.Chang L, Chang M, Chang HM, et al. Microsatellite instability: a predictive biomarkers for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018;26(2);e15-21.Google Scholar
- 42.Strickland KC, Howitt BE, Rodig SJ, et al. Immunogenicity of clear cell ovarian cancer: association with ARID1A loss, microsatellite instability and endometriosis. J Clin Oncol. 2016; 34. Abstract available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.5514. Accessed Sept 27th 2017.
- 44.Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–23.CrossRefGoogle Scholar
- 45.Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98.CrossRefGoogle Scholar
- 54.Hinrichs CS, Stevanovic S, Draper L, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. Presented at: 2014 ASCO Annual Meeting Press Briefing; June 2, 2014; Chicago, IL. Abstract LBA3008.Google Scholar